心理护理干预及健康教育对复发性尖锐湿疣的护理效果评价

目的评价心理护理干预及健康教育对复发性尖锐湿疣的护理效果影响。方法选取2014年5月至2018年1月四川大学华西医院诊治的87例复发性尖锐湿疣患者作为研究对象。87例复发性尖锐湿疣患者随机分成两组。对照组采用激光治疗联合口服阿维A疗法,再附以常规护理;观察组在对照组基础上,加强心理护理干预及健康教育;两组均随访6个月。结果观察组42例(95.45%)治愈,对照组33例(76.74%)治愈,差异具有统计学意义(P0.05)。结论心理护理干预及健康教育作为治疗尖锐湿疣的辅助治疗与护理手段,提高了患者治疗与护理的依从性,减少了疾病的复发,有较强的临床运用价值。     

5-氨基酮戊酸光动力疗法治疗复发性尖锐湿疣65例疗效观察

目的观察5-氨基酮戊酸光动力疗法(ALA-PDT)治疗复发性尖锐湿疣的临床疗效及复发率。方法65例复发性尖锐湿疣患者局部外敷5-盐酸氨酮戊酸(ALA)后,用波长635nm的氦氖激光照射疣体,每次20～40min,1次/ w,共治疗1～6次;对照组为55例初发尖锐湿疣患者,用传统CO_2激光常规治疗。比较两组的疗效及复发率。结果治疗组经1～6次治疗后疣体完全消退,无溃疡、尿道狭窄、感染等并发症,术后随访3个月复发7(10.77%)例。对照组经1～2次治疗后疣体全部清除,术后随访3个月复发26(47.27%)例,其中19(34.55%)例在1～3周内复发。结论ALA -PDT治疗尖锐湿疣疗效可靠、复发率低、耐受性好。     

复发性尖锐湿疣及生殖器疱疹患者心理状况和婚姻质量调查

目的:调查复发性尖锐湿疣及生殖器疱疹患者的心理状态和婚姻质量。方法:采用了临床症状自评量表(Symptom Checklist 90,SCL-90)和Olson婚姻质量问卷对来诊的复发性尖锐湿疣及生殖器疱疹患者进行了随机抽样问卷凋查,并与复发性较低的STD患者进行对照分析。结果:58例复发性尖锐湿疣及生殖器疱疹患者在抑郁、焦虑、人际关系敏感、敌对性、恐怖、偏执、精神病性等方面得分高于对照组;而在婚姻满意度、性格相容性、夫妻交流、业余活动、性生活、与亲友关系等方面得分低于对照组,差异有统计学意义(P<0.05)。结论:复发性尖锐湿疣及生殖器疱疹患者存在着较严重的心理卫生问题,其婚姻生活质量欠佳。     

四君子汤加减对复发性尖锐湿疣患者血清IL-2、IL-4水平的影响与疗效观察

目的:通过观察四君子汤加减对复发性尖锐湿疣患者血清白细胞介素4(IL-4)和白细胞介素2(IL-2)的影响,探讨四君子汤加减治疗复发性尖锐湿疣的机理。方法:将80例复发性尖锐湿疣患者经除疣治疗后随机分为治疗组与对照组,治疗组给予中药治疗。检测两组患者治疗前后血清IL-4、IL-2的水平,同时观察两组治疗后疣体的复发情况。结果:治疗组治疗后血清IL-4水平较治疗前降低,且低于治疗后对照组水平,差异均具有统计学意义(P0.05)。治疗组治疗后血清IL-2水平较治疗前升高,且明显高于治疗后对照组的水平,差异均具有统计学意义(P0.05)。治疗后治疗组复发率为17.14%,明显低于对照组,差异具有统计学意义(P0.05)。结论:四君子汤加减能调节机体的细胞免疫功能,可有效防治尖锐湿疣的复发。     

高频电离子联合艾拉光动力治疗男性复发性尖锐湿疣疗效观察

目的:分析并探讨高频电离子联合艾拉光动力治疗男性复发性尖锐湿疣的临床效果。方法:选取在我院接受治疗的男性复发性尖锐湿疣患者120例,随机分成两组,分别为观察组与对照组,每组60例。两组患者均给予高频电离子方案进行治疗,在此基础上,观察组联合艾拉光动力进行治疗。治疗后4周、8周和12周随访。观察随访结果,评估治疗效果和复发情况以及不良反应发生情况。结果:观察组治愈率为91.67%,复发率为8.33%。对照组治愈率为71.67%,复发率为28.33%。观察组治愈率明显高于对照组,复发率明显低于对照组(P0.05)。观察组不良反应发生率为6.67%,对照组不良反应发生率为31.67%。观察组不良反应发生率明显低于对照组(P0.05)。结论:高频电离子联合艾拉光动力治疗男性复发性尖锐湿疣效果显著,且复发率低,临床上值得推广。     

复方虎杖散颗粒联合胸腺肽对复发性生殖疱疹的临床观察

目的:探讨观察复方虎杖散颗粒联合胸腺肽对复发性生殖疱疹的临床疗效。方法:病例选择我院在2013年1月至2015年1月收治的复发性生殖疱疹患者共106例,依照随机数表法划分为治疗组54例、对照组52例。其中,对照组采用胸腺肽注射治疗,治疗组采用复方虎杖散颗粒联合胸腺肽进行治疗。观察两组患者症状消失、止疱、结痂、皮损愈合时间,治疗前后IL-2、IFN-γ水平,治疗有效率,患者复发情况及不良反应情况。结果:经过治疗,治疗组患者症状消失时间(4.49±1.06)d、止疱时间(1.58±0.39)d、结痂时间(2.37±0.71)d、皮损愈合时间(3.34±0.95)d,均低于对照组(P0.05),差异有统计意义;治疗组患者IL-2水平(323.64±28.31)pg/mL、IFN-γ水平(323.57±19.07)pg/mL,改善情况均优于对照组(217.48±11.95)pg/mL、(232.89±14.66)pg/mL,差异有统计意义(P0.05);治疗组治愈总有效率96.30%,优于对照组82.69%,差异有统计意义(P0.05);治疗组患者复发尖锐湿疣4例、衣原体属感染性尿道炎2例,治疗控制率88.89%,明显优于对照组复发尖锐湿疣11例、衣原体属感染性尿道炎8例,控制率63.46%,差异有统计意义(P0.05)。结论:复方虎杖散颗粒联合胸腺肽治疗复发性生殖疱疹症状消失快、疗效好、复发率低,值得临床推广。     

5-氨基酮戊酸光动力疗法联合CO_2激光治疗复发性尖锐湿疣疗效观察

目的:比较外用药、CO_2激光及5-氨基酮戊酸光动力疗法(ALA-PDT)联合CO_2激光3种方法治疗复发性尖锐湿疣的疗效,探索一种能有效降低尖锐湿疣复发的方法.方法:分别采用外用药、CO_2激光、ALA-PDT联合CO_2激光治疗39例复发性尖锐湿疣患者,并进行回顾性分析.结果:对39例患者随访3～12个月,均先开始外用鬼臼毒素酊治疗,平均41 d在原皮损部位出现新的皮损.复发率为100%.再采用CO_2激光治疗,平均57 d复发,复发率为100%.最后经ALA-PDT联合CO_2激光治疗,复发率降至5.1%(2例),对复发患者再次采用联合疗法治疗1次达痊愈.结论:ALA-PDT联合CO_2激光治疗复发性尖锐湿疣可明显降低复发率(P＜0.01),且安全、耐受性好,无明显不良反应.     

疣毒净对复发性尖锐湿疣患者淋巴细胞凋亡调控蛋白的影响

目的 :　观察中药疣毒净系列制剂对复发性尖锐湿疣患者淋巴细胞凋亡调控蛋白的影响。方法 :　选择经疣毒净系列制剂治疗前、后复发性尖锐湿疣患者血液行淋巴细胞凋亡调控蛋白Bcl - 2、CD95 + 、CD95L的检测并与健康人群进行对照。结果 :　复发性尖锐湿疣患者治疗前后CD95 + 、CD95L表达水平高于健康对照组 ,Bcl- 2则低于健康对照组 (P<0 .0 5 ) ,而治疗前组CD95 + 、CD95L表达水平分别高于治疗后组 (P <0 .0 5 ) ,Bcl- 2则低于治疗后组 (P <0 .0 1)。结论 :　经疣毒净治疗后抗凋亡能力有明显提高     

男性尖锐湿疣患者外周血性激素检测

目的　探讨性激素与男性复发性尖锐湿疣的关系。方法　选择 5 9例男性复发性尖锐湿疣患者以及 5 2例经 1次治疗后未复发的男性尖锐湿疣患者 ,分别检测性激素 ,并进行比较。结果　 5 9例男性复发性尖锐湿疣的孕酮(PROG)值 1.0 995± 0 .495 5 ,明显高于 5 2例未复发者的PROG值 0 .8474± 0 .473 1,P <0 .0 0 5。结论　PROG值高的男性尖锐湿疣患者复发的可能性较大     

心理护理干预联合健康教育对复发性尖锐湿疣的护理效果观察

目的:观察心理护理干预联合健康教育对复发性尖锐湿疣的护理效果。方法:将2018年6月-2019年3月期间我院收治的80例尖锐湿疣患者随机分为对照组(40例)和观察组(40例),均采取二氧化碳激光或高频电灼方式烧灼患处皮损治疗。对照组接受常规护理,观察组接受心理护理干预与健康教育,6个月后观察两组复发率及护理满意度等指标。结果:观察组复发率(7.5%)明显低于对照组(25.0%),差异有统计学意义(2=4.50,P<0.05);观察组护理满意度为(90.2±2.5)分,明显高于对照组[(87.5±3.1)分],差异有统计学意义(t=4.29,P<0.05)。结论:心理护理干预联合健康教育在复发性尖锐湿疣的护理中应用效果明显,值得推广。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Occupational allergic contact dermatitis caused by decorative plants

12 cases of occupational allergic contact dermatitis caused by decorative plants were diagnosed in a 14-year period. The patients were middle-aged, and their average exposure time was 13 years. The plant families and plants causing occupational contact dermatitis were Compositae (5 patients: chrysanthemum, elecampane, gerbera, feverfew), Alstroemeriaceae (5 patients, Alstroemeria ), Liliaceae (4 patients; tulip, hyacinth). Amaryllidaceae (2 patients: narcissus) and Caryophyllaceae (2 patients; carnation, cauzeflower). The known chemical allergens causing dermatitis were tuliposide-A and sesquiterepene lactones, such as alantolactones and parthenolide, in the Liliaceae and Compositae families. 7 of the 12 patients were able to continue their work; 5 were not because of severe relapses of skin symptoms. The plant allergen and extract series currently available are of great help in the diagnosis.     

Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐Studiengruppe

Background: Pemphigus vulgaris is a potentially life‐threatening autoimmune disorder of the skin and mucous membranes characterized by antibodies against epidermal adhesion molecules. Clinically characteristic are painful chronic blisters or erosions of mucous membranes and skin. There are no published studies on the impact o this disease on quality of life. Patients and methods: This registration was performed within the scope of the German BSD (Bullous Skin Disease) study group, from November 1997 until January 2002. A total of 36 patients with the first diagnosis of pemphigus vulgaris were registered at the university hospitals of Dresden, Erlangen, Kiel, Mannheim, München and Würzburg. Thirty of the 36 (83 %) patients participated in the quality of life questionnaire utilizing the German version of ‘Dermatology Life Quality Index’ (DLQI) provided by A. Y. Finlay. The DLQI varies from 0 to 30 with an increased DLQI score indicating a decrease in quality of quality. Results: The overall DLQI total score of 10 ± 6,7 in the investigated pemphigus patients was significantly increased in comparison to other skin diseases. Conclusions: These results suggest that the DLQI can be a very useful additional outcome criteria for clinical studies with pemphigus vulgaris and in the treatment of these patients.